ARMONAIR DIGIHALER Drug Patent Profile
✉ Email this page to a colleague
When do Armonair Digihaler patents expire, and when can generic versions of Armonair Digihaler launch?
Armonair Digihaler is a drug marketed by Teva Pharm and is included in one NDA. There are five patents protecting this drug.
The generic ingredient in ARMONAIR DIGIHALER is fluticasone propionate. There is one drug master file entry for this compound. Seventy-six suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Armonair Digihaler
A generic version of ARMONAIR DIGIHALER was approved as fluticasone propionate by ENCUBE on May 14th, 2004.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ARMONAIR DIGIHALER?
- What are the global sales for ARMONAIR DIGIHALER?
- What is Average Wholesale Price for ARMONAIR DIGIHALER?
Summary for ARMONAIR DIGIHALER
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 86 |
| Patent Applications: | 2,700 |
| Drug Prices: | Drug price information for ARMONAIR DIGIHALER |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ARMONAIR DIGIHALER |
| What excipients (inactive ingredients) are in ARMONAIR DIGIHALER? | ARMONAIR DIGIHALER excipients list |
| DailyMed Link: | ARMONAIR DIGIHALER at DailyMed |
US Patents and Regulatory Information for ARMONAIR DIGIHALER
ARMONAIR DIGIHALER is protected by five US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Pharm | ARMONAIR DIGIHALER | fluticasone propionate | POWDER;INHALATION | 208798-008 | Apr 8, 2022 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Teva Pharm | ARMONAIR DIGIHALER | fluticasone propionate | POWDER;INHALATION | 208798-006 | Feb 20, 2020 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Teva Pharm | ARMONAIR DIGIHALER | fluticasone propionate | POWDER;INHALATION | 208798-004 | Feb 20, 2020 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ARMONAIR DIGIHALER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Teva Pharm | ARMONAIR DIGIHALER | fluticasone propionate | POWDER;INHALATION | 208798-004 | Feb 20, 2020 | ⤷ Start Trial | ⤷ Start Trial |
| Teva Pharm | ARMONAIR DIGIHALER | fluticasone propionate | POWDER;INHALATION | 208798-005 | Feb 20, 2020 | ⤷ Start Trial | ⤷ Start Trial |
| Teva Pharm | ARMONAIR DIGIHALER | fluticasone propionate | POWDER;INHALATION | 208798-005 | Feb 20, 2020 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ARMONAIR DIGIHALER
See the table below for patents covering ARMONAIR DIGIHALER around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2011254958 | ⤷ Start Trial | |
| Brazil | 112012029106 | ⤷ Start Trial | |
| Canada | 2799625 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ARMONAIR DIGIHALER
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1305329 | 08C0014 | France | ⤷ Start Trial | PRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111 |
| 1305329 | SPC/GB08/026 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080116; UK EU/1/07/434/002 20080116; UK EU/1/07/434/003 20080116 |
| 1519731 | 92269 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch